Finance

Lists
DNTH:NASDAQ
Dianthus Therapeutics Inc
$113.70
0.00%
(0.00) 1D
Aug 19, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DNTH...
Mkt. cap
6.36B
Avg. vol.
859.81K
Volume
386.00
52-wk high
$117.88
52-wk low
$22.76
EPS
-$4.15
Beta
1.22
Shares outstanding
55.93M
No. of employees
92
Mkt. cap
6.36B
Avg. vol.
859.81K
Volume
386.00
52-wk high
$117.88
52-wk low
$22.76
EPS
-$4.15
Beta
1.22
Shares outstanding
55.93M
No. of employees
92
News stories
From web sources and news partners
About Dianthus Therapeutics Inc
CEO-
Employees92
Founded2019
Headquarters-
SectorBiotechnology
Websitedianthustx.com
Analyst ratings
Based on 13 analysts giving stock ratings to DNTH in the past 3 months
Strong buy
Buy
13
Hold
0
Sell
0
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for DNTH in the last 3 months.
Highest
Current $113.70
$200.00 (+75.90%)
Average
$140.64 (+23.69%)
Lowest
$122.00 (+7.30%)
Analyst
Recommendation
Action
Price target
Projected
Date
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
$133.00
+17%
08/13/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Maintained
$134.00
+17.9%
08/10/2026
Danielle Brill
Truist Financial
Buy
Maintained
$128.00
+12.6%
08/06/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
$200.00
+75.9%
08/05/2026
Swayampakula Ramakanth
H.C. Wainwright
Buy
Reiterated
$158.00
+39%
08/06/2026
Laura Chico
Wedbush
Buy
Maintained
$122.00
+7.3%
08/05/2026
Sadia Rahman
Wells Fargo
Buy
Maintained
$135.00
+18.7%
08/05/2026
William Maughan
Clear Street
Buy
Maintained
$130.00
+14.3%
08/05/2026
Yaron Werber
TD Cowen
Buy
Reiterated
$150.00
+31.9%
08/05/2026
Rami Katkhuda
LifeSci Capital
Buy
Maintained
$125.00
+9.9%
08/04/2026
Myles Minter
William Blair
Buy
Reiterated
-
-
08/04/2026
Maury Raycroft
Jefferies
Buy
Maintained
$132.00
+16.1%
06/15/2026
Ryan Deschner
Raymond James
Buy
Maintained
-
-
06/12/2026
Andy Chen
Wolfe Research
Buy
Maintained
$98.00
-13.8%
04/08/2026
Colleen M. Kusy
Robert W. Baird
Buy
Maintained
$132.00
+16.1%
03/09/2026
Trevor Allred
Oppenheimer
Buy
Maintained
$145.00
+27.5%
03/09/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
396.00K
284.00K
463.00K
761.00K
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
32.49M
59.92M
34.53M
48.69M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.20M
9.91M
12.47M
13.56M
Operating expense
40.68M
69.82M
47.00M
62.24M
Total operating expenses
40.68M
69.82M
47.00M
62.24M
Operating income
-40.29M
-69.54M
-46.53M
-61.48M
Other non operating income
-360.00K
-409.00K
-249.00K
-370.00K
EBT including unusual items
-36.76M
-64.43M
-40.83M
-50.22M
EBT excluding unusual items
-39.30M
-65.54M
-41.75M
-55.97M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-36.76M
-64.43M
-40.83M
-50.22M
Net profit margin
-9,284.09%
-22,687.32%
-8,819.44%
-6,598.55%
Earnings per share
-0.97
-1.43
-0.85
-0.90
Interest and investment income
1.35M
4.41M
5.05M
5.89M
Interest expense
-
-
-
-
Net interest expenses
1.35M
4.41M
5.05M
5.89M
Depreciation and amortization charges
-
-
-
-
EBITDA
-40.26M
-69.51M
-46.50M
-61.44M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps